Targeting CD146 with a 64 Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas
Abstract
Unfortunately, current practices for diagnosis and treatment of glioblastoma have failed to improve overall patient survival, which has galvanized the emergence of novel strategies based on targeting tumor-specific antigens. Herein, we show for the first time, to our knowledge, that CD146 is a promising target for noninvasive in vivo imaging and targeted therapy of glioblastoma. We developed a 64 Cu-radiolabeled anti-CD146 antibody (YY146) that allowed the sensitive and specific detection of subcutaneous and orthotopic brain tumors using positron emission tomography. Additionally, YY146 showed therapeutic effects on U87MG brain cancer cells and was able to preferentially stain human resected high-grade glioma tumors. These findings indicate the clinical relevance of our antibody and its potential role in patient diagnosis, stratification, and targeted therapy.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 09, 2015
- Source ID
- 10.1073/pnas.1502648112
Entities
People
- Christina M. Lewis
- Christopher G. England
- Jinrong Wu
- Jun Rao
- Li Yin
- Mary E. Meyerand
- Pu Wang
- Reinier Hernandez
- Robert J. Nickles
- Stephen A. Graves
- Weibo Cai
- Xiu-wu Bian
- Yazhuo Qu
- Yunan Yang
Organizations
- American Cancer Society
- Army Medical University
- Chinese Academy of Sciences
- National Institutes of Health
- National Science Foundation
- United States Department of Defense
- University of Wisconsin–Madison